Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lattice Biologics (V.LBL) CEO moves to revolutionize cancer diagnosis

Gaalen Engen Gaalen Engen, .
3 Comments| April 27, 2016

{{labelSign}}  Favorites
{{errorMessage}}

Lattice Biologics (TSX: V.LBL, Forum) is a biotech venture working in the field of cellular therapies and tissue engineering with a focus on bone, skin and cartilage regeneration. Its Extracelluar Matrix Technology has made Lattice an emerging leader in the sector as it develops and processes biologic allograft products for both domestic and international markets. More recently the company has expanded its portfolio and through the use of its ECM technology is developing a disruptive cancer diagnostic technique that is sure to revolutionize the way oncologists treat their patients. Have a listen as I speak with Lattice Biologics CEO, Guy Cook, to get a better understanding of the company and the potential it holds.



--Gaalen Engen
https://twitter.com/gaalenengen

FULL DISCLOSURE: Lattice Biologics is a Stockhouse Publishing client.


{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company